Medicover Genetics Launches OncoSentia MRD for Unresectable NSCLC
Medicover Genetics launched OncoSentia MRD for unresectable non-small cell lung cancer.
Related stories
Canaccord Genuity reports second-quarter fiscal 2027 results
Canaccord Genuity reported quarterly earnings per common share of $0.43, excluding significant items, for the quarter ended September 30, 2026.
M impact | EQUITY | Nov 15, 2026, 11:22 PM UTC
Samsung SDI to Supply Batteries to Jupiter Power
Samsung SDI says it will supply batteries to Jupiter Power for three years starting in 2029.
M impact | EQUITY | Nov 15, 2026, 11:18 PM UTC
More Than 10,000 US Flights Affected for Third Day
US air travel disruptions continued Sunday, with Transportation Secretary Sean Duffy predicting a return to normal by Monday as airlines worked to restore schedules.
M impact | EQUITY | Nov 15, 2026, 11:11 PM UTC
Thousands of US Flights Canceled, Delayed for Third Day in a Row
M impact | EQUITY | Nov 15, 2026, 11:11 PM UTC
Boeing-Lockheed Rocket Fails Mid-Flight, Destroying Amazon Satellites
M impact | EQUITY | Nov 15, 2026, 11:09 PM UTC
Samsung SDI Wins 16 GWh Battery Order From Jupiter Power
Samsung SDI's U.S. subsidiary signed an order for 16 GWh of batteries from Jupiter Power.
M impact | EQUITY | Nov 15, 2026, 11:05 PM UTC